Fig. 5From: Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinomaUtilities of FGF19 as a biomarker for recurrence prediction. (a) Cumulative RFS rate based on serum FGF19 levels before ablation therapy. (b) Changes in the serum FGF19 levels after the ablation therapy against HCC. (c) Relationship between non-normalization and an unexpected increase in the FGF19 levels after the ablation therapy and early recurrenceBack to article page